Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions

Journal Name: Drug Metabolism and Personalized Therapy Issue: Ahead of print
Source: Drug Metabolism and Personalized Therapy - Category: Drugs & Pharmacology Source Type: research